Splenic marginal zone lymphoma

Blood Reviews

Volumn 19, Issue 1, 2005, Pages 39-51

  Oscier, David ^a   Owen, Roger ^b   Johnson, Stephen ^c  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

Clinical and diagnostic features; Splenic lymphoma with villous lymphocytes; Splenic marginal zone lymphoma; Treatment

Indexed keywords

ALKYLATING AGENT; CD20 ANTIBODY; CHLORAMBUCIL; CLADRIBINE; COTRIMOXAZOLE; FLUDARABINE; IMMUNOGLOBULIN; PENTOSTATIN; PURINE; PURINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ANEMIA; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; B CELL LYMPHOMA; BLOOD; BLOOD TOXICITY; BONE MARROW; CELL STRUCTURE; CELL TRANSFORMATION; CHROMOSOME 7Q; CLINICAL FEATURE; CYTOGENETICS; DEATH; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENE TRANSLOCATION; GENETIC DISORDER; HEMATOLOGIC DISEASE; HEMOLYSIS; HUMAN; IMMUNOGLOBULIN GENE; IMMUNOPHENOTYPING; INCIDENTAL FINDING; LARGE CELL LYMPHOMA; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPLEEN; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; TRISOMY;

EID: 9644296038     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2004.03.002     Document Type: Article

References (80)

1. Troussard X., Valensi F., Duchayne E., et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). Br. J. Haematol. 93:1996;731-736
2. Melo J.V., Hegde U., Parreira A., Thompson I., Lampert I.A., Catovsky D. Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens. J. Clin. Pathol. 40:1987;642-651
3. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J. Clin. Pathol. 42:1989;567-584
4. Schmid C., Kirkham N., Diss T., Isaacson P.G. Splenic marginal zone cell lymphoma. Am. J. Surg. Pathol. 16:1992;455-466
5. Isaacson P.G., Matutes E., Burke M., Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood. 84:1994;3828-3834
6. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 84:1994;1361-1392
7. Isaacson P.G., Piris M.A., Catovsky D., et al. Splenic marginal zone lymphoma. Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tumours. 2001;135-137 IARCPress, Lyon
8. Armitage J.O., Weisenburger D.D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J. Clin. Oncol. 16:1998;2780-2795
9. Thieblemont C., Felman P., Callet-Bauchu E., et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 4:2003;95-103
10. Franco V., Florena A.M., Iannitto E. Splenic marginal zone lymphoma. Blood. 101:2003;2464-2472
11. Chacon J.I., Mollejo M., Munoz E., et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 100:2002;1648-1654
12. Parry-Jones N., Matutes E., Gruszka-Westwood A.M., Swansbury G.J., Wotherspoon A.C., Catovsky D. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br. J. Haematol. 120:2003;759-764
13. Berger F., Felman P., Thieblemont C., et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 95:2000;1950-1956
14. Murakami H., Irisawa H., Saitoh T., et al. Immunological abnormalities in splenic marginal zone cell lymphoma. Am. J. Hematol. 56:1997;173-178
15. Sawamura M., Yamaguchi S., Murakami H., et al. Multiple autoantibody production in a patient with splenic lymphoma. Ann. Hematol. 68:1994;251-254
16. Gale R., Smith O.P., Wood M., Mehta A.B. Splenic lymphoma with villous lymphocytes complicated by autoimmune haemolytic anaemia. Lancet. 340:1992;1106
17. Tefferi A., Hanson C.A., Kurtin P.J., Katzmann J.A., Dalton R.J., Nichols W.L. Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br. J. Haematol. 96:1997;850-853
18. Phanish M.K., Owen A., Parry D.H. Spontaneous regression of acquired C1 esterase inhibitor deficiency associated with splenic marginal zone lymphoma presenting with recurrent angio-oedema. J. Clin. Pathol. 55:2002;789-790
19. Thieblemont C., Felman P., Berger F., et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin. Lymphoma. 3:2002;41-47
20. Owen R.G. Extramedullary sites of involvement in hematologic malignancies: case 2. Lymphocyte morphology in splenic marginal zone lymphoma. J. Clin. Oncol. 20:2002;342-344
21. Audouin J., Le Tourneau A., Molina T., et al. Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br. J. Haematol. 122:2003;404-412
22. Mollejo M., Menarguez J., Lloret E., et al. Splenic marginal zone lymphoma: a distinctive type of low-grade B-cell lymphoma. A clinicopathological study of 13 cases. Am. J. Surg. Pathol. 19:1995;1146-1157
23. Mollejo M., Algara P., Mateo M.S., et al. Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma? Histopathology. 40:2002;22-30
24. Mollejo M., Lloret E., Menarguez J., Piris M.A., Isaacson P.G. Lymph node involvement by splenic marginal zone lymphoma: morphological and immunohistochemical features. Am. J. Surg. Pathol. 21:1997;772-780
25. Camacho F.I., Mollejo M., Mateo M.S., et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am. J. Surg. Pathol. 25:2001;1268-1276
26. Lloret E., Mollejo M., Mateo M.S., et al. Splenic marginal zone lymphoma with increased number of blasts: an aggressive variant? Hum. Pathol. 30:1999;1153-1160
27. Matutes E., Morilla R., Owusu-Ankomah K., Houlihan A., Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood. 83:1994;1558-1562
28. Matutes E., Morilla R., Owusu-Ankomah K., Houliham A., Meeus P., Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 14(Suppl 1):1994;57-61
29. Oscier D.G., Matutes E., Gardiner A., et al. Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br. J. Haematol. 85:1993;487-491
30. Sole F., Salido M., Espinet B., et al. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica. 86:2001;71-77
31. Hernandez J.M., Garcia J.L., Gutierrez N.C., et al. Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am. J. Pathol. 158:2001;1843-1850
32. Thieblemont C., Nasser V., Felman P., et al. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood. 103(7):2004;2727-2737
33. Oscier D.G., Gardiner A., Mould S. Structural abnormalities of chromosome 7q in chronic lymphoproliferative disorders. Cancer Genet. Cytogenet. 92:1996;24-27
34. Gruszka-Westwood A.M., Hamoudi R., Osborne L., Matutes E., Catovsky D. Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes. Genes Chromosomes Cancer. 36:2003;57-69
35. Mateo M., Mollejo M., Villuendas R., et al. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am. J. Pathol. 154:1999;1583-1589
36. Oscier D.G., Davis Z., Parker A., Mould S., Chapman R.M., Orchard J.A. Splenic marginal zone lymphoma and splenic lymphoma with villous lymphocytes: a single disease entity [abstract]. Blood. 100:2002;286b
37. Hernandez J.M., Schoenmakers E.F., Dal Cin P., Michaux L., Van de Ven W.J., Van den B.H. Molecular delineation of the commonly deleted segment in mature B-cell lymphoid neoplasias with deletion of 7q. Genes Chromosomes Cancer. 18:1997;147-150
38. Gruszka-Westwood A.M., Matutes E., Coignet L.J., Wotherspoon A., Catovsky D. The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br. J. Haematol. 104:1999;600-604
39. Gazzo S., Baseggio L., Coignet L., et al. Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma. Haematologica. 88:2003;31-38
40. Martinez-Climent J.A., Sanchez-Izquierdo D., Sarsotti E., et al. Genomic abnormalities acquired in the blastic transformation of splenic marginal zone B-cell lymphoma. Leuk Lymphoma. 44:2003;459-464
41. Cuneo A., Bardi A., Wlodarska I., et al. A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma. Leukemia. 15:2001;1262-1267
42. Brito-Babapulle V., Gruszka-Westwood A.M., Platt G., et al. Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia. Haematologica. 87:2002;357-362
43. Corcoran M.M., Mould S.J., Orchard J.A., et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 18:1999;6271-6277
44. Sonoki T., Harder L., Horsman D.E., et al. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood. 98:2001;2837-2844
45. Jadayel D., Matutes E., Dyer M.J., et al. Splenic lymphoma with villous lymphocytes: analysis of BCL-1 rearrangements and expression of the cyclin D1 gene. Blood. 83:1994;3664-3671
46. Sanchez-Izquierdo D., Buchonnet G., Siebert R., et al. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood. 101:2003;4539-4546
47. Baldini L., Fracchiolla N.S., Cro L.M., et al. Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin. Blood. 84:1994;270-278
48. Gruszka-Westwood A.M., Hamoudi R.A., Matutes E., Tuset E., Catovsky D. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood. 97:2001;3552-3558
49. Tierens A., Delabie J., Malecka A., et al. Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. Am. J. Pathol. 162:2003;681-689
50. Algara P., Mateo M.S., Sanchez-Beato M., et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood. 99:2002;1299-1304
51. Zhu D., Orchard J., Oscier D.G., Wright D.H., Stevenson F.K. V(H) gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo. Blood. 100:2002;2659-2661
52. Zhu D., Oscier D.G., Stevenson F.K. Splenic lymphoma with villous lymphocytes involves B cells with extensively mutated Ig heavy chain variable region genes. Blood. 85:1995;1603-1607
53. Zhu D., Thompsett A.R., Bedu-Addo G., Stevenson F.K., Bates I. VH gene sequences from a novel tropical splenic lymphoma reveal a naive B cell as the cell of origin. Br. J. Haematol. 107:1999;114-120
54. Bahler D.W., Pindzola J.A., Swerdlow S.H. Splenic marginal zone lymphomas appear to originate from different B cell types. Am. J. Pathol. 161:2002;81-88
55. Tierens A., Delabie J., Michiels L., Vandenberghe P., Wolf-Peeters C. Marginal-zone B cells in the human lymph node and spleen show somatic hypermutations and display clonal expansion. Blood. 93:1999;226-234
56. Bates I., Bedu-Addo G. Chronic malaria and splenic lymphoma: clues to understanding lymphoma evolution. Leukemia. 11:1997;2162-2167
57. Hermine O., Lefrere F., Bronowicki J.P., et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N. Engl. J. Med. 347:2002;89-94
58. Savilo E., Campo E., Mollejo M., et al. Absence of cyclin D1 protein expression in splenic marginal zone lymphoma. Mod. Pathol. 11:1998;601-606
59. Mollejo M., Lloret E., Solares J., Bergua J.M., Mateo M., Piris M.A. Splenic involvement by blastic mantle cell lymphoma (large cell/anaplastic variant) mimicking splenic marginal zone lymphoma. Am. J. Hematol. 62:1999;242-246
60. Nathwani B.N., Anderson J.R., Armitage J.O., et al. Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Project. Hum. Pathol. 30:1999;263-268
61. Owen R.G., Barrans S.L., Richards S.J., et al. Waldenstrom macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am. J. Clin. Pathol. 116:2001;420-428
62. Seve P., Felman P., Gouillat C., Charhon A., Broussolle C. [Splenic lymphoma with villous lymphocytes and Waldenstrom disease: diagnostic difficulties by way of a case report]. Rev. Med. Int. 19:1998;839-841
63. Ghia P., Prato G., Scielzo C., Stella S., Geuna M., Guida G., Caligaris-Cappio F. Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood. 103(6):2004;2337-2342
64. Baldini L., Guffanti A., Cro L., et al. Poor prognosis in non-villous splenic marginal zone cell lymphoma is associated with p53 mutations. Br. J. Haematol. 99:1997;375-378
65. Mulligan S.P., Matutes E., Dearden C., Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br. J. Haematol. 78:1991;206-209
66. Kroft S.H., Singleton T.P., Dahiya M., Ross C.W., Schnitzer B., Hsi E.D. Ruptured spleens with expanded marginal zones do not reveal occult B-cell clones. Mod. Pathol. 10:1997;1214-1220
67. Catovsky D., Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin. Hematol. 36:1999;148-154
68. Marti G.E. The role of splenectomy in splenic marginal zone B-cell lymphoma. Clin. Lymphoma. 3:2002;48
69. Davies J.M., Barnes R., Milligan D. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin. Med. 2:2002;440-443
70. Franco V., Florena A.M., Stella M., et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer. 91:2001;294-301
71. El Weshi A., Ribrag V., Girinski T., El Hajj M., Dhermain F., Bayle C. Low and medium dose spleen radiation therapy are able to induce long-term responses in splenic lymphoma with villous lymphocytes. Br. J. Haematol. 103:1998;1212-1213
72. Bolam S., Orchard J., Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br. J. Haematol. 99:1997;158-161
73. Lefrere F., Hermine O., Belanger C., et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia. 14:2000;573-575
74. Yasukawa M., Yamauchi H., Azuma T., Takada K., Ishimura M., Fujita S. Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes. Eur. J. Haematol. 69:2002;112-114
75. Virchis A., Mehta A. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CdA). Br. J. Haematol. 100:1998;609
76. Lefrere F., Hermine O., Francois S., et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma. 40:2000;113-117
77. Iannitto E., Cirrincionne S., Pagliaro M., et al. Pentostatin in the treatment of splenic lymphoma with villous lymphocytes. A phase II study. Preliminary results [abstract]. Blood. 98:2001;132a-133a
78. Iannitto E., Ambrosetti A., Ammatuna E., et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematological findings in a series of 57 patients [abstract]. Blood. 100:2002;160a-160b
79. Thomas D., O'Brian S., Cortes J., et al. Treatment of splenic lymphoma with villous lymphocytes (SLVL) and marginal zone lymphoma (MZL) with single agent Rituximab [abstract]. Blood. 98:2001;134a
80. Daniels J., Perkins J., Byrd J. Rituximab is effective for patients with splenic lymphoma with villous lymphocytes [abstract]. Blood. 100:2002;312b